Uveitis Treatment Market Outlook 2031
The global uveitis treatment market size was valued at USD 606 Million in 2022 and is likely to reach USD 998 Million by 2031, expanding at a CAGR of 5.7% during the forecast period, 2023-2031. The growth of the market is attributed to the increasing instances of the uveitis disease and the latest diagnosis to treat them.
Uveitis is described to be a series of inflammatory diseases which produces unnatural swelling and destroys the host’s eye tissues. The range of uveitis varies from slightly reduced vision with irritating itches to severe vision loss. The uvea found in the eye consists of eye blood vessels which grows thinner in the middle layer.
Once these vessels get strained out of proportion due to uneven lighting or damage taken, the uvea gets damaged, and this becomes the initial symptoms of uveitis. According to the World Health Organization or the WHO along with several colleges of optometrists across the globe, there are 30,000 new cases every year with over 10% leading to complete blindness.
The COVID-19 pandemic has reduced the growth of the global uveitis market. Researchers and scientists were not able to understand the relationship between the coronavirus and uveitis. People have started to become more accustomed to indoor activities involving long hours of binge watching, which can be harmful for the eyes in the long run.
Therefore, the analysts believe that once the COVID-19 pandemic is controlled and when hospitals will be functioning at maximum efficiency, patients will start attending their eye diseases, fueling the global uveitis treatment market growth in the long run.
Uveitis Treatment Market Trends, Drivers, Restraints, and Opportunities
- Increase in occurrences of eye diseases which can be treated with the help of latest techniques is the primary reason for the projection of boosting the global market growth during the forecast period, 2023-2031.
- There has been a significant increase in the research and development activities leading to technological advancement of uveitis treatment which can become a major factor boosting the market growth.
- High prices for the development of uveitis treatment devices and high cost of services from the company’s perspective is anticipated to hinder the global uveitis treatment market growth. This becomes extremely difficult to function in developing countries such as India, South Africa, and Brazil where there is limited healthcare infrastructure.
- Uveitis can lead to other diseases including AIDS to which doctors and physicians have still not being able to find co-relations between them. This uncertainty hinders the market growth.
- R&D activities have found new methodologies in the treatment of eye diseases using new methodologies. Small Incision Lenticule Extraction or the SMILE has found more preference over the traditional LASIK surgery being more cost and efficacy effective.
Scope of Uveitis Treatment Market Report
The report on the global uveitis treatment market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Uveitis Treatment Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, and Analgesics), Disease Types (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), Causes (Infectious and Non-infectious), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
Key Players Covered in the Report
Allergan Inc; Bausch & Lomb Incorporated; Santen Pharmaceutical Co Ltd; AbbVie Inc; Novartis AG; Eyegate Pharmaceuticals Inc; Regeneron Pharmaceuticals; Eyepoint Pharmaceuticals Inc; and Alimera Sciences Inc
Global Uveitis Treatment Market Segment Insights
Corticosteroid segment is anticipated to signify the largest market share
Based on types, the global uveitis treatment market is segmented into corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics. The corticosteroids segment is expected to constitute the major share of the market in 2019. The growth of this segment is attributed to fact that this is the primary treatment preferred by patients while facing complicated eye diseases including uveitis.
Meanwhile the monoclonal antibodies segment is anticipated to grow with a significant CAGR during the forecast period, 2023-2031 owing to the swift advancement of drugs which follow the monoclonal antibodies formula.
Anterior uveitis segment is projected to register a large market share
Based on disease types, the global uveitis treatment market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment is expected to constitute the major share of the market in 2019 due to the high occurrence rates of this disease to all age segments, be it small children or adults over the age of 60 years. This disease can also be fatal to the point of losing vision, meaning the treatment of this disease is absolutely essential.
Meanwhile posterior uveitis is anticipated to grow with a significant CAGR during the forecast period, 2023-2031 owing to availability to various drugs that can be treated. Posterior uveitis is showing more occurrences especially during the COVID pandemic and treatment innovations have been focused on this disease more.
Non-infectious segment is estimated to signify the largest market share
Based on causes, the global uveitis treatment market is bifurcated into infectious and noninfectious. The noninfectious segment is expected to constitute the major share of the market in 2019. This growth is attributed to the widespread of these diseases combined with the numerous treatment diagnosis available for them.
Meanwhile the infectious segment is also anticipated to grow with a significant CAGR during the forecast period, 2023-2031 owing to the increasing incidences especially by the coronavirus, and the complete dedication of the research & development teams of hospitals towards finding the cure of these diseases.
Hospital pharmacies segment is anticipated to register a huge market share
On the basis of distribution channels, the global uveitis treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the availability from a large array of alternatives from the management perspective to diagnose eye inflammations.
Meanwhile the online pharmacies segment is anticipated to grow with a significant CAGR during the forecast period, 2023-2031 owing to the increasing convenience on the choosing from multiple online websites where the patient can select the specific drugs for the treatment. This increases the safety factor as well, especially during the pandemic periods.
Uveitis Treatment Market Regional Outlook
North America is anticipated to dominate the market
On the basis of regions, the global uveitis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to constitute the largest share in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology.
The demand of uveitis treatment is increasing rapidly in this region due to the presence of the major market players in the market, an advantage other region does not have. The cost of expenditure is significantly lower in North America than that of other economies. The presence of a well-developed healthcare infrastructure along with the presence of numerous start-ups fueled the regional market growth as well.
However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2023-2031. Most of the countries such as China and India are rapidly reaching the economic developed status with the disposable income of the population increasing exponentially.
The governments have also started relaxing health insurance policies, so that the research and development teams of government hospital institutions can pursue further on complicated sciences which includes uveitis treatment. Multiple multinational pharmaceutical organizations and other companies have started to invest heavily in the further diagnostics of uveitis, its cost factor, and its overall benefits.
Other countries such as Japan, Singapore, and Australia have exceeded the technological advancement to that of the developed economies, made a robust healthcare infrastructure to provide advanced diagnostics services including the uveitis treatment to the majority of their population.
- Monoclonal Antibodies
- Cycloplegic Agents
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Major players competing in the global uveitis treatment market are Allergan Inc; Bausch & Lomb Incorporated; Santen Pharmaceutical Co Ltd; AbbVie Inc; Novartis AG; Eyegate Pharmaceuticals Inc; Regeneron Pharmaceuticals; Eyepoint Pharmaceuticals Inc; and Alimera Sciences Inc.
These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Eyepoint Pharmaceuticals Inc have finished developing a new implant called the YUTIQ II, which later got approved by the Food and Drug Administration in 2020, which is used in the treatment of noninfectious uveitis.